Soodamani Thangavel

This inventor holds 13 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Syngene International Limited. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Soodamani Thangavel. Retrieved from https://idiyas.com/inventor/soodamani-thangavel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 9.9

ph-index = 2

Forward Citations = 30(Granted Patents)

Location History:

Hosur, IN (2019 - 2020)
Krishnagiri, IN (2017 - 2024)
Bengaluru, IN (2024)

Company Filing History:

15 out of 3,742

Bristol-Myers Squibb Compnay

patents

2 out of 7

Syngene International Limited

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319676 - Substituted amide compounds useful as farnesoid X receptor modulators (2025-06-03),

2. 12059420 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2024-08-13),

3. 12030835 - Substituted amide compounds useful as farnesoid X receptor modulators (2024-07-09),

4. 11713312 - Substituted bicyclic compounds as farnesoid X receptor modulators (2023-08-01),

5. 11254663 - Substituted bicyclic compounds as farnesoid X receptor modulators (2022-02-22),

6. 11253525 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2022-02-22),

7. 10959986 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2021-03-30),

8. 10544120 - Biaryl kinase inhibitors (2020-01-28),

9. 10399932 - Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer (2019-09-03),

10. 10246469 - Biaryl kinase inhibitors (2019-04-02),

11. 10174044 - Fused pyridines as kinase inhibitors (2019-01-08),

12. 10167254 - IDO inhibitors (2019-01-01),

13. 9790169 - IDO inhibitors (2017-10-17),

Title: Soodamani Thangavel: Innovator in Pharmaceutical Compounds

Introduction

Soodamani Thangavel is a prominent inventor based in Krishnagiri, India, known for his significant contributions to the field of pharmaceuticals. With a total of 13 patents to his name, he has made remarkable advancements in the development of compounds that target various health conditions.

Latest Patents

Among his latest patents is a groundbreaking invention related to substituted amide compounds that serve as farnesoid X receptor modulators. This patent discloses compounds that can modulate the activity of the farnesoid X receptor (FXR), which is crucial in treating diseases associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders. Another notable patent involves inhibitors of indoleamine 2,3-dioxygenase (IDO), which are designed to treat proliferative disorders, including cancer and autoimmune diseases.

Career Highlights

Soodamani has worked with esteemed companies such as Bristol-Myers Squibb Company and Syngene International Limited. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Throughout his career, Soodamani has collaborated with notable colleagues, including Susheel Jethanand Nara and Srinivas Cheruku. These partnerships have contributed to the success of his innovative projects.

Conclusion

Soodamani Thangavel's work in developing pharmaceutical compounds has made a significant impact on the medical field. His inventions continue to pave the way for new treatments and therapies that address critical health issues.

Profile summary based on public USPTO records.